Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other neoplasm 1

Conditions

Precancerous Conditions 4Breast Neoplasms 4Neoplasms 2Adenomatous Polyposis Coli 2Unspecified Adult Solid Tumor, Protocol Specific 1Tobacco Use Disorder 1Squamous Cell Carcinoma of Head and Neck 1Rectal Neoplasms 1Pain 1Melanoma 1Leukoplakia, Oral 1Inflammation 1Hypertension 1Desmoid Tumors 1Coproporphyria 1Colonic Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Intraductal, Noninfiltrating 1Breast Carcinoma In Situ 1

Interventions

Carboplatin 341Paclitaxel 262Cisplatin 233Pemetrexed 226Docetaxel 206Erlotinib Hydrochloride 193Gemcitabine 178pembrolizumab 137Bevacizumab 121Radiotherapy 118Nivolumab 84Gefitinib 73Vinorelbine 64Cetuximab 58atezolizumab 47Afatinib 46durvalumab 44osimertinib 41Radiosurgery 35Ipilimumab 34Drug Therapy 32Taxes 30Albumin-Bound Paclitaxel 29130-nm albumin-bound paclitaxel 29Surgical Procedures, Operative 28Etoposide 25Irinotecan 24Sorafenib 21Cyclophosphamide 20Radiation 19

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Carcinoma, Non-Small-Cell Lung × Sulindac × Clear all
NCT00368927 2014-05-23

Sulindac in Preventing Lung Cancer in Current or Former Smokers With Bronchial Dysplasia

National Cancer Institute (NCI)

Phase 2 Completed
61 enrolled 11 charts
Other neoplasmThoracic

Carcinoma, Non-Small-Cell Lung, Precancerous Conditions, Tobacco Use Disorder

Data powered by HemOnc (CC BY 4.0) Colophon âš¡